MedTrace Logo

An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients

NCT01844791 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-10-21

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with Platinum-Gemcitabine based doublet first line therapy in stage IV non-small cell lung cancer (NSCLC) patients.

Conditions

Interventions

DRUG

OCZ103-OS

OCZ103-OS is given in combination with chemotherapy each cycle

DRUG

Platinum

Platinum is given as standard chemotherapy each cycle

DRUG

Gemcitabine

Gemcitabine is given as standard chemotherapy each cycle

Sponsors & Collaborators

  • Oncozyme Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Ewa Kalinka-Warzocha, MD-PhD · Wojewodzki Szpital Specjalistyczny im .M. Kopernika w

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01844791 on ClinicalTrials.gov